XBiotech Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| XBIT | XLO | XINT.ST | MBX.TO | ACTI.ST | XFOR | |
|---|---|---|---|---|---|---|
| Market cap | 59.45M | 57.31M | 124.45M | 39.72M | 101.09M | 321.24M |
| P/E (TTM) | — | — | — | — | — | 162.0 |
| Forward P/E | 15.0 | -15.0 | — | 14.5 | — | -4.2 |
| Price/book | 0.5 | 0.8 | -4.5 | 1.6 | 2.7 | 1.6 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −6.13% | −25.22% | −60.80% | +20.00% | −42.74% | −7.56% |
| Today | −2.01% | +0.35% | +0.35% | −3.33% | +4.21% | +2.21% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All XBIT news ›XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis
IND Application for V-SPINE Study Completes 30-Day FDA Review Without Clinical Hold, Clearing Path for U.S. Patient Enrollment Study Chair and the Axial Spondyloarthritis Scientific Advisory Board The advisory panel includes: About the…
XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer
Investigator-sponsored study funded by the French National Cancer Institute (INCa) meets pre-specified primary efficacy success criterion with 61.... XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored…
XBiotech to enroll patients in vilamakitug trial following FDA review
XBiotech (XBIT) announced that its investigational new drug, or IND, application for V-SPINE, a Phase II, double-blind, placebo-controlled, rand... XBiotech to enroll patients in vilamakitug trial following FDA review XBiotech (XBIT)…
XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.
XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.businessinsider.com3
- markets.financialcontent.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 4 articles, not a forecast.